首页|Polo样激酶1抑制剂Rigosertib对细胞放射损伤的防护作用

Polo样激酶1抑制剂Rigosertib对细胞放射损伤的防护作用

扫码查看
DNA双链断裂是电离辐射诱发最严重DNA损伤,能启动细胞周期阻滞、修复和死亡系列信号反应,其中周期阻滞是DNA损伤应答的重要过程,为DNA损伤修复提供了充足的时间.周期蛋白依赖性激酶 4/6(cyclin-dependent kinase 4/6,CDK4/6)、周期蛋白依赖性激酶 1(cyclin-dependent kinase1,CDK1)和Polo样激酶1(Polo-like kinase 1,PLK1)等是细胞周期调控关键激酶,其抑制剂可以阻滞细胞周期进程,是否具有细胞放射防护作用有待进一步探究.本文选择人宫颈癌细胞HeLa、人正常乳腺细胞MCF-10A以及人脐静脉上皮细胞HUVEC为研究对象,研究比较了 PLK1抑制剂Rigosertib、Volasertib,CDK4/6抑制剂Palbocilib,CDK1抑制剂Ro-3306的辐射防护作用.流式细胞术检测表明,Rigosertib、Volasertib、Ro-3306 将细胞阻滞于 G2 期(P<0.05,P<0.01 或 P<0.001),Palbocilib将细胞阻滞于G1期(P<0.05,P<0.01或P<0.001).免疫荧光检测结果显示,Rigosertib、Volasertib、Ro-330 可显著减少 γ 射线照射后 γH2AX foci 数目(P<0.001),表明上述药物可促进DNA修复.HR和NHEJ报告系统证实,Rigosertib、Ro-3306同时通过同源重组和非同源末端连接2种修复途径提高DNA修复效率(P<0.05或P<0.001),Palbocilib、Volasertib能提高HR修复效率(P<0.01).从上述结果优选出PLK1抑制剂Rigosertib进行深入研究,发现Ri-gosertib 可显著降低辐射诱导的细胞凋亡(P<0.05或P<0.01).CCK-8和克隆形成实验证实,Ri-gosertib 促进受照后细胞的增殖与存活率(P<0.05,P<0.01或P<0.001).综上所述,我们分析比较了 Rigosertib、Volasertib、Palbocilib、Ro-3306四种药物对细胞放射敏感性的影响,其中Rigosertib保护细胞免受辐射损伤最为显著,为放射损伤防护药物的研发提供了新的技术路径和实验依据.
Radioprotection of PLK1 Inhibitor Rigosertib in Cells
Radiation-induced DNA double-strand break(DSB)is the most serious type of DNA damage,which can trigger a series of DNA damage response(DDR)signaling,such as cell cycle arrest,DNA re-pair,apoptosis,etc.As an important process of DDR,cell cycle arrest is considered to provide sufficient time for DNA damage repair before cell division to prevent the damage DNA delivered to daughter cells.PLK1,CDK1 and CDK4/6 are important kinases of controlling cell cycle progression,and the inhibitors of these kinases can block cell cycle at certain phases.Whether they have radioprotective effect needs to be further explored.In this study,human cervical cancer HeLa cells,human normal breast MCF-10A cells and human umbilical vein epithelial cells(HUVEC)were used to determine the radioprotective effects of PLK1 inhibitors Rigosertib,Volasertib,CDK4/6 inhibitor Palbocilib and CDK1 inhibitor Ro-3306,and the related mechanisms were investigated.Flow cytometry assay demonstrated that Rigosertib,Volasertib,and Ro-3306 blocked cells in G2 phase(P<0.05,P<0.01,or P<0.001),and Palbo-cilib blocked cells in G,phase(P<0.05,P<0.01,or P<0.001).Immunofluorescence staining as-say demonstrated that Rigosertib,Volasertib,and Ro-330 significantly reduced the number of γH2AX fo-ci after γ-ray irradiation(P<0.001),suggesting that the above agents could promote DNA repair effi-ciency.HR and NHEJ reporter assays confirmed that Rigosertib and Ro-3306 promoted DNA repair via both pathways of DSBs repair simultaneously efficiency(P<0.05 or P<0.001),and Palbocilib and Volasertib could promote HR efficiency.From the above results,the PLK1 inhibitor Rigosertib was pref-erentially selected for further study.It was found that Rigosertib significantly reduced radiation-induced apoptosis(P<0.05 or P<0.01).CCK-8 and colony formation assays demonstrated that Rigosertib promoted the proliferation and viability of irradiated cells(P<0.05,P<0.01 or P<0.001).In sum-mary,we analyzed and compared the effects of four agents,Rigosertib,Volasertib,Palbocilib and Ro-3306,on the radiosensitivity of cells,among which Rigosertib protects the cells from radiation damage most efficiently.We provide a new strategy and experimental bases for the development of radiation pro-tection drugs.

cell cycle arrestradiosensitivityradiation protectionRigosertibDNA damage repair

孙星瑶、谭金鹏、谢达菲、高山山、周平坤

展开 >

南华大学衡阳医学院军事医学研究院研究生协作培养基地辐射医学研究所北京市放射生物学重点实验室,湖南衡阳 421001

南华大学衡阳医学院,湖南衡阳 421001

军事科学院军事医学研究院辐射医学研究所北京市放射生物学重点实验室,北京 100850

周期阻滞 放射敏感性 辐射防护 Rigosertib DNA损伤修复

2024

中国生物化学与分子生物学报
中国生物化学与分子生物学会 北京大学

中国生物化学与分子生物学报

CSTPCD北大核心
影响因子:0.617
ISSN:1007-7626
年,卷(期):2024.40(5)
  • 27